NKGen Biotech (NKGN) Competitors

NKGen Biotech logo
$0.63 -0.14 (-17.93%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$0.59 -0.04 (-6.50%)
As of 02/14/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NKGN vs. RVPH, BYSI, GANX, ME, FBLG, AADI, QNCX, VHAQ, CNTX, and KALA

Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Reviva Pharmaceuticals (RVPH), BeyondSpring (BYSI), Gain Therapeutics (GANX), 23andMe (ME), FibroBiologics (FBLG), Aadi Bioscience (AADI), Quince Therapeutics (QNCX), Viveon Health Acquisition (VHAQ), Context Therapeutics (CNTX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

NKGen Biotech vs.

Reviva Pharmaceuticals (NASDAQ:RVPH) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Reviva Pharmaceuticals has higher earnings, but lower revenue than NKGen Biotech. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reviva PharmaceuticalsN/AN/A-$39.26M-$1.11-1.62
NKGen Biotech$80K354.54-$82.94M-$5.08-0.12

Reviva Pharmaceuticals received 27 more outperform votes than NKGen Biotech when rated by MarketBeat users.

CompanyUnderperformOutperform
Reviva PharmaceuticalsOutperform Votes
27
90.00%
Underperform Votes
3
10.00%
NKGen BiotechN/AN/A

Reviva Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

In the previous week, NKGen Biotech had 6 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 7 mentions for NKGen Biotech and 1 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.80 beat NKGen Biotech's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Reviva Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NKGen Biotech
0 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Reviva Pharmaceuticals currently has a consensus target price of $11.40, indicating a potential upside of 533.33%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reviva Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Company Net Margins Return on Equity Return on Assets
Reviva PharmaceuticalsN/A N/A -252.53%
NKGen Biotech N/A N/A -479.36%

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 74.7% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Reviva Pharmaceuticals beats NKGen Biotech on 9 of the 14 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGN vs. The Competition

MetricNKGen BiotechBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$28.36M$3.09B$5.77B$20.30B
Dividend YieldN/A1.67%5.27%3.67%
P/E Ratio-0.1245.4925.6545.09
Price / Sales354.54399.83475.1116.18
Price / CashN/A192.7646.0620.33
Price / Book-0.244.057.275.73
Net Income-$82.94M-$40.60M$3.19B$1.00B
7 Day Performance67.86%3.50%1.67%0.13%
1 Month Performance43.34%4.18%4.11%1.37%
1 Year Performance-57.93%-10.55%22.10%16.03%

NKGen Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGN
NKGen Biotech
N/A$0.63
-17.9%
N/A-57.9%$28.36M$80,000.00-0.12N/AGap Down
High Trading Volume
RVPH
Reviva Pharmaceuticals
4.0934 of 5 stars
$2.04
-1.7%
$11.40
+457.7%
-58.1%$68.05MN/A-1.835
BYSI
BeyondSpring
N/A$1.73
+3.6%
N/A+30.6%$67.52M$1.75M0.0080
GANX
Gain Therapeutics
2.2729 of 5 stars
$2.52
-3.6%
$7.25
+188.3%
-43.4%$66.70M$50,000.00-2.2920
ME
23andMe
1.8878 of 5 stars
$2.56
+1.0%
$9.40
+267.9%
-83.6%$66.50M$219.64M-0.16770
FBLG
FibroBiologics
2.9264 of 5 stars
$1.77
-4.8%
$13.00
+634.0%
-90.9%$64.99MN/A0.0010Short Interest ↓
High Trading Volume
AADI
Aadi Bioscience
1.3895 of 5 stars
$2.61
-6.0%
$1.67
-36.0%
+36.3%$64.34M$24.35M-1.1440
QNCX
Quince Therapeutics
1.5434 of 5 stars
$1.43
-3.7%
$9.50
+566.7%
+9.4%$62.70MN/A-1.1560
VHAQ
Viveon Health Acquisition
N/A$11.00
flat
N/A-4.3%$62.26MN/A0.002High Trading Volume
CNTX
Context Therapeutics
1.5204 of 5 stars
$0.83
-5.1%
$6.33
+664.0%
-21.0%$62.18MN/A-0.917Short Interest ↑
KALA
KALA BIO
4.0504 of 5 stars
$10.16
-7.8%
$15.00
+47.7%
+18.2%$61.85M$3.89M-0.8130

Related Companies and Tools


This page (NYSE:NKGN) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners